Vicore Pharma AB’s Post

Looking to make a difference in the lives of patients with #ipf? Come join our dynamic team at Vicore and be a part of this exciting new stage of growth! We are currently looking to hire Clinical Science Liaisons (#CSLs) in the US and Europe. Read more about these opportunities and apply here: US: https://lnkd.in/e-ExDCBj UK: https://lnkd.in/eXxxZNpA Germany/Austria: https://lnkd.in/eGXfEkq7 #TeamVicore #hiring

Come join our fantastic team! We are looking for a QA Manager GMP to our office in Hørsholm, Denmark. Read more about the position and apply here: https://lnkd.in/d2FnpeTf

Vicore Pharma AB is pleased to announce positive final results from the Phase 2a AIR trial demonstrating that buloxibutid improves lung function over 36 weeks in patients with idiopathic pulmonary fibrosis (#IPF). These encouraging results were presented yesterday by Toby Maher, Keck School of Medicine of USC, as a late-breaking oral session at the American Thoracic Society International Congress (#ATS2024). Vicore will be discussing the results in more detail during a webinar on Wednesday 5/22 at 10:00 ET/16:00 CET. You can register for the webinar here: https://lnkd.in/eKp8xYGj #pulmonaryfibrosis #biotechnews #respiratory #clinicaldata

Vicore at the Clinical Trials booth at #ATS2024 in San Diego. Come see us, we’re presenting phase 2a data and starting phase 2b. Jimmy Nolin, Ph.D. Åsa Magnusson, Ahmed Mousa, Jimmie Hofman, Jessica Shull, Cecilia Ganslandt, Johan Raud, May-Lill Garly, MD PhD, Professor Bertil E. Lindmark MD, PhD

We are pleased to announce that Mikael Nygård, VP Operations and Corporate Strategy, will present recent and upcoming activities at Aktiespararnas digital life science event today. Register to the event in the link below and tune in at 15:20 CET: https://lnkd.in/g_7YRn9J

Vicore is pleased to announce that our digital therapy, Almee, has received Breakthrough Device Designation from the FDA. Almee is the first digital therapy to address anxiety and quality of life in patients living with pulmonary fibrosis. The Breakthrough Program designates those medical devices that are evaluated as providing a more effective treatment for life-threatening or irreversibly debilitating diseases. Wonderful work from the team and of course, very impressive work from Alex Therapeutics.

Our CEO, Ahmed Mousa, was recently featured on the Drug Discovery World 'In Conversation With' podcast, where he discussed Vicore Pharma AB ATRAG formulations for rare lung diseases. Listen to the episode here as we explore the potential of this new class of drug candidates: bit.ly/4cb1hh2 #VicorePharma #IPF #ATRAGs

Director of Digital Health, Jessica Shull PhD, will be a panellist at BIO Europe Spring this March 18-20 in Barcelona. The topic: Unleashing healthcare: the power of AI, data, and personalized therapies. Co-panelists are from Johnson & Johnson Innovation and the Barcelona Supercomputing Center. Sure to be insightful. https://lnkd.in/eFC6-S4M

Vicore Pharma AB is pleased to announce its participation at two investor conferences this Wednesday, March 6th. We invite you to join us as we share the latest updates on our portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (#IPF).   CEO, Ahmed Mousa, will be presenting at the @Cowen Inc. 44th Annual Health Care Conference in Boston, MA, at 12:50 PM ET/6:50 PM CET. Watch the live webcast here: bit.ly/49xDHJt.   Concurrently, Mikael Nygård, VP of Operations and Corporate Strategy, will be presenting at the Carnegie Investment Bank Nordic Healthcare Seminar at 9:00 AM ET/3:00 PM CET.   For full details, please visit: bit.ly/3IeqvgT